James P. Morden

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Christopher M. Nutting, James P. Morden, Kevin J. Harrington et al. · The Lancet Oncology · 2011 · 1.7K citations · Full text

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

Ben O’Leary, Sarah Hrebien, James P. Morden et al. · Nature Communications · 2018 · 404 citations · Full text

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial

Ian Smith, J.F.R. Robertson, Lucy Kilburn et al. · The Lancet Oncology · 2020 · 299 citations · Full text

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial

Stephen Johnston, Shannon Puhalla, Duncan Wheatley et al. · Journal of Clinical Oncology · 2018 · 224 citations · Full text

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial

Adrian Murray Brunt, Duncan Wheatley, John Yarnold et al. · Radiotherapy and Oncology · 2016 · 218 citations · Full text